Kalehua Capital Management’s TScan Therapeutics TCRX Stock Holding History

Kalehua Capital Management’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$446K	Buy	+454,876	New	+$485K	0.26%	26

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Kalehua Capital Management's TCRX Position: Q2 2026 in Review

Kalehua Capital Management opened a new position in TScan Therapeutics (TCRX) in Q2 2026: 454,876 shares worth $446K. The stake represents 0.26% of the portfolio and ranks #26 among its holdings.

60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

Kalehua Capital Management held 454,876 shares of TScan Therapeutics worth $446K as of Q2 2026.
TScan Therapeutics was a new Kalehua Capital Management position in Q2 2026.
TScan Therapeutics made up 0.26% of Kalehua Capital Management's portfolio in Q2 2026, its #26 holding.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Kalehua Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.